These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 28102540)

  • 1. Radiation recall dermatitis associated with nivolumab for metastatic malignant melanoma.
    Korman AM; Tyler KH; Kaffenberger BH
    Int J Dermatol; 2017 Apr; 56(4):e75-e77. PubMed ID: 28102540
    [No Abstract]   [Full Text] [Related]  

  • 2. No recurrence of nivolumab-induced idiopathic thrombocytopenic purpura in a metastatic melanoma patient switched to ipilimumab.
    Takimoto R; Otsuka A; Kaku Y; Honda T; Kabashima K
    Eur J Dermatol; 2018 Feb; 28(1):84-85. PubMed ID: 29400292
    [No Abstract]   [Full Text] [Related]  

  • 3. Nivolumab-associated bullous pemphigoid reactions involving multiple epitopes.
    Aoki Y; Miyagawa F; Miyashita K; Nishimura Y; Hashimoto T; Asada H
    Eur J Dermatol; 2019 Oct; 29(5):552-554. PubMed ID: 31570326
    [No Abstract]   [Full Text] [Related]  

  • 4. Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab.
    Page B; Borradori L; Beltraminelli H; Yawalkar N; Hunger RE
    J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):e256-e257. PubMed ID: 28430376
    [No Abstract]   [Full Text] [Related]  

  • 5. Subcutaneous Fat Necrosis During Nivolumab Therapy for Metastatic Melanoma.
    Pach J; Olamiju B; Weiss S; Damsky W; Leventhal J
    JAMA Dermatol; 2021 Apr; 157(4):468-469. PubMed ID: 33688919
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of a patient with HIV and metastatic melanoma with consequitive ipilimumab and nivolumab.
    Tomsitz D; Hein R; Biedermann T; Kohlmeyer J
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e26-e28. PubMed ID: 28662283
    [No Abstract]   [Full Text] [Related]  

  • 7. Isolated adrenocorticotropic hormone deficiency possibly caused by nivolumab in a metastatic melanoma patient.
    Fujimura T; Kambayashi Y; Furudate S; Kakizaki A; Hidaka T; Haga T; Hashimoto A; Morimoto R; Aiba S
    J Dermatol; 2017 Mar; 44(3):e13-e14. PubMed ID: 27440178
    [No Abstract]   [Full Text] [Related]  

  • 8. Case of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab in a patient with advanced malignant melanoma.
    Wada N; Uchi H; Furue M
    J Dermatol; 2017 Aug; 44(8):e196-e197. PubMed ID: 28391613
    [No Abstract]   [Full Text] [Related]  

  • 9. Nivolumab PD-1 inhibitor immunotherapy associated with vulvar, perineal and perianal lichen sclerosus.
    Wernham AGH; Shah F; Velangi S
    Clin Exp Dermatol; 2019 Mar; 44(2):e22-e23. PubMed ID: 30430637
    [No Abstract]   [Full Text] [Related]  

  • 10. Isolated Adrenocorticotropic Hormone Deficiency in Melanoma Patients Treated with Nivolumab.
    Kitano S; Tatsuno K; Ishibe J; Shimauchi T; Fujiyama T; Ito T; Ogawa N; Tokura Y
    Acta Derm Venereol; 2018 Jul; 98(7):704-705. PubMed ID: 29405244
    [No Abstract]   [Full Text] [Related]  

  • 11. Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab.
    Kuwatsuka Y; Iwanaga A; Kuwatsuka S; Okubo Y; Murayama N; Ishii N; Hashimoto T; Utani A
    J Dermatol; 2018 Jan; 45(1):e21-e22. PubMed ID: 28944534
    [No Abstract]   [Full Text] [Related]  

  • 12. Scleroderma-like syndrome associated with nivolumab treatment in malignant melanoma.
    Cho M; Nonomura Y; Kaku Y; Nakabo S; Endo Y; Otsuka A; Kabashima K
    J Dermatol; 2019 Jan; 46(1):e43-e44. PubMed ID: 29863795
    [No Abstract]   [Full Text] [Related]  

  • 13. Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma.
    Alnabulsi R; Hussain A; DeAngelis D
    Orbit; 2018 Oct; 37(5):381-384. PubMed ID: 29381409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential occurrence of primary and secondary hypothyroidism during treatment with nivolumab: pitfalls in immuno-oncological therapy and endocrinological diagnostic procedures.
    Ansorge C; Seufert J; Meiss F; von Bubnoff D
    J Dtsch Dermatol Ges; 2018 Dec; 16(12):1483-1485. PubMed ID: 30411844
    [No Abstract]   [Full Text] [Related]  

  • 15. Induction of Immune Reaction in Benign Melanocytic Nevi Without Halo During Nivolumab Therapy in a Patient With Melanoma.
    Nakamura Y; Fujino T; Kagamu H; Matsuya T; Teramoto Y; Asami Y; Yamamoto A
    JAMA Dermatol; 2017 Aug; 153(8):832-834. PubMed ID: 28492864
    [No Abstract]   [Full Text] [Related]  

  • 16. Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy.
    Chin CK; Hall S; Green C; Van Hazel G; Spagnolo D; Cheah CY
    Eur J Cancer; 2019 Jul; 115():84-87. PubMed ID: 31129384
    [No Abstract]   [Full Text] [Related]  

  • 17. [Vitiligo under checkpoint inhibitors].
    Amini-Adle M; Dalle S
    Ann Dermatol Venereol; 2018 Oct; 145(10):633-635. PubMed ID: 29866472
    [No Abstract]   [Full Text] [Related]  

  • 18. Nivolumab-induced colitis in a patient with malignant melanoma: A case report and immunological analysis.
    Miyashita A; Fukushima S; Tsukamoto H; Itai H; Miyamoto H; Nakahara S; Kubo Y; Kimura T; Kuriyama H; Ihn H
    J Dermatol; 2019 Sep; 46(9):e339-e341. PubMed ID: 30908699
    [No Abstract]   [Full Text] [Related]  

  • 19. Stevens-Johnson syndrome associated with radiation recall dermatitis in a patient treated with nivolumab.
    Rouyer L; Bursztejn AC; Charbit L; Schmutz JL; Moawad S
    Eur J Dermatol; 2018 Jun; 28(3):380-381. PubMed ID: 29952288
    [No Abstract]   [Full Text] [Related]  

  • 20. 79-year Old Man on Nivolumab with Itchy Erythematous Patches.
    Copur MS; Corey S
    Oncology (Williston Park); 2020 Feb; 34(2):53-54. PubMed ID: 32645195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.